Daiichi Sankyo Daichirona for intramuscular injection for booster vaccination approved in Japan as Omicron XBB.1.5-adapted Monovalent mRNA Vaccine against COVID

Tokyo: Daiichi Sankyo has announced that DAICHIRONA FOR INTRAMUSCULAR INJECTION (DS-5670) for booster vaccination has been approved in Japan as an Omicron XBB.1.5-adapted monovalent mRNA vaccine against COVID-19.

Daiichi Sankyo had submitted a supplemental New Drug Application (sNDA) to Japan’s Ministry of Health, Labour and Welfare (MHLW) for manufacturing and marketing approval of the Omicron XBB.1.5-adapted monovalent mRNA vaccine in September 2023.

"Based on the supply agreement with the MHLW, Daiichi Sankyo will commence the distribution of this first-ever Japan-made mRNA vaccine in the coming days and is committed to supply a total of 1.4 million doses in FY2023 for the current special temporary vaccination program against COVID-19 in Japan," the Company stated.

DAICHIRONA FOR INTRAMUSCULAR INJECTION can be distributed and stored under refrigeration (2–8°C), offering improved convenience to healthcare professionals.

Read also: Daiichi Sankyo Vanflyta approved in EU as First FLT3 Inhibitor specifically for newly Diagnosed FLT3-ITD Positive AML

Read also: AstraZeneca-Daiichi Sankyo Enhertu approved in EU for lung cancer